Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Role of the normal gut microbiota
Jandhyala, S. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8787 · Cited by 3,001
The gut microbiota, bacterial metabolites and colorectal cancer
Louis, P., Hold, G. L., & Flint, H. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3344 · Cited by 2,816
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
“Earlier studies on the association between bacteria and cancer have focused primarily on exploring (i) the role of bacteria in tumor pathogenesis, (ii) the potential of gut bacteria to modulate anti-tumor immune responses (18, 19), and (iii) the contribution of bacterial metabolism to the adverse effects of chemothera…”
BackgroundSchwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Self-citationGarrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications
Wong, S. H., & Yu, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0209-8 · Cited by 1,331
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
Chemical transformation of xenobiotics by the human gut microbiota
Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017) · Science · doi:10.1126/science.aag2770 · Cited by 1,080
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Gut microbiota imbalance and colorectal cancer
Gagnière, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.501 · Cited by 845
Bäckhed, F., Fraser, C. M., Ringel, Y., Sanders, M. E., Sartor, R. B., Sherman, P. M., Versalovic, J., Young, V., & Finlay, B. B. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.10.012 · Cited by 836
Microbes, Microbiota, and Colon Cancer
Sears, C. L., & Garrett, W. S. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.007 · Cited by 818
Mechanisms and consequences of intestinal dysbiosis
Weiss, G. A., & Hennet, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2509-x · Cited by 775
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753
“Overall, these data suggest that AFMT could be a promising tool compound for the study of bacterial L-dopa metabolism (56) and highlight the promise of developing L-dopa–based combination therapies containing drugs that target both host and gut microbial decarboxylation.”
Plottel, C. S., & Blaser, M. J. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.10.003 · Cited by 743
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Microbiome-wide association studies link dynamic microbial consortia to disease
Gilbert, J. A., Quinn, R. A., Debelius, J., Xu, Z. Z., Morton, J., Garg, N., Jansson, J. K., Dorrestein, P. C., & Knight, R. (2016) · Nature · doi:10.1038/nature18850 · Cited by 718
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2013) · Science · doi:10.1126/science.1235872 · Cited by 704
Gut microbiome-host interactions in health and disease
Kinross, J. M., Darzi, A. W., & Nicholson, J. K. (2011) · Genome Medicine · doi:10.1186/gm228 · Cited by 691
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656
The role of the microbiome in cancer development and therapy
Bhatt, A. P., Redinbo, M. R., & Bultman, S. J. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21398 · Cited by 653
“In preclinical studies, mice receiving concurrent treatment with b-glucuronidase inhibitors were protected from irinotecaninduced diarrhea.(133) Other chemotherapeutic agents also have adverse effects in the GI tract.”
BackgroundSelf-citationBedarf, J. R., Hildebrand, F., Coelho, L. P., Sunagawa, S., Bahram, M., Goeser, F., Bork, P., & Wüllner, U. (2017) · Genome Medicine · doi:10.1186/s13073-017-0428-y · Cited by 642
Flores, R., Shi, J., Fuhrman, B., Xu, X., Veenstra, T. D., Gail, M. H., Gajer, P., Ravel, J., & Goedert, J. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-253 · Cited by 615
“For example, inhibition of fecal microbial β-glucuronidases may be possible [37], although the relatively weak associations that we found between fecal β-glucuronidase activity and urinary estrogens suggest that enzyme inhibition would not markedly reduce systemic estrogen levels.”
BackgroundCarbohydrate-active enzymes (CAZymes) in the gut microbiome
Wardman, J. F., Bains, R. K., Rahfeld, P., & Withers, S. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00712-1 · Cited by 597
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Specialized metabolites from the microbiome in health and disease
Sharon, G., Garg, N., Debelius, J., Knight, R., Dorrestein, P. C., & Mazmanian, S. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.016 · Cited by 544
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
How Probiotics Affect the Microbiota
Wieërs, G., Belkhir, L., Enaud, R., Leclercq, S., Philippart de Foy, J.-M., Dequenne, I., de Timary, P., & Cani, P. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00454 · Cited by 525
The Intestinal Microbiome and Estrogen Receptor–Positive Female Breast Cancer
(2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw029 · Cited by 523
Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies
Aggarwal, N., Kitano, S., Puah, G. R. Y., Kittelmann, S., Hwang, I. Y., & Chang, M. W. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00431 · Cited by 508
Personalized Mapping of Drug Metabolism by the Human Gut Microbiome
Javdan, B., Lopez, J. G., Chankhamjon, P., Lee, Y.-C. J., Hull, R., Wu, Q., Wang, X., Chatterjee, S., & Donia, M. S. (2020) · Cell · doi:10.1016/j.cell.2020.05.001 · Cited by 474
Human Gut Microbiota and Gastrointestinal Cancer
Meng, C., Bai, C., Brown, T. D., Hood, L. E., & Tian, Q. (2018) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.06.002 · Cited by 467
Cancer and the gut microbiota: An unexpected link
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
The microbiome and gynaecological cancer development, prevention and therapy
Łaniewski, P., Ilhan, Z. E., & Herbst-Kralovetz, M. M. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0286-z · Cited by 450
The Gut Microbial Endocrine Organ: Bacterially Derived Signals Driving Cardiometabolic Diseases
Brown, J. M., & Hazen, S. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-060513-093205 · Cited by 438
“Inhibition of the bacterial β-glucuronidase enzyme responsible for this reaction was shown to improve the effectiveness of this chemotherapeutic while decreasing deleterious side effects (82).”
BackgroundMicrobial shifts in the aging mouse gut
Langille, M. G., Meehan, C. J., Koenig, J. E., Dhanani, A. S., Rose, R. A., Howlett, S. E., & Beiko, R. G. (2014) · Microbiome · doi:10.1186/s40168-014-0050-9 · Cited by 437
“, CPT-11) leading to severe diarrhea and thus limiting the efficacy of the drug [45,46].”
BackgroundErvin, S. M., Li, H., Lim, L., Roberts, L. R., Liang, X., Mani, S., & Redinbo, M. R. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010950 · Cited by 397
“Because we know precisely where and how the glucuronide moiety binds (11, 12, 25, 27, 28), and these substrate molecules have a limited number of rotatable bonds, we know with reasonable certainty where these estrogens are within the active site.”
BackgroundInfluentialSelf-citationBeyond gut feelings: how the gut microbiota regulates blood pressure
Marques, F. Z., Mackay, C. R., & Kaye, D. M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.120 · Cited by 397
Modulating the microbiome to improve therapeutic response in cancer
McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376
The fast-growing field of photo-driven theranostics based on aggregation-induced emission
Zhang, Z., Kang, M., Tan, H., Song, N., Li, M., Xiao, P., Yan, D., Zhang, L., Wang, D., & Tang, B. Z. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01138c · Cited by 374
The Intestinal Metabolome: An Intersection Between Microbiota and Host
Ursell, L. K., Haiser, H. J., Van Treuren, W., Garg, N., Reddivari, L., Vanamala, J., Dorrestein, P. C., Turnbaugh, P. J., & Knight, R. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.001 · Cited by 355
The gut microbiome: an orchestrator of xenobiotic metabolism
Collins, S. L., & Patterson, A. D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.001 · Cited by 348
Fuhrman, B. J., Feigelson, H. S., Flores, R., Gail, M. H., Xu, X., Ravel, J., & Goedert, J. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2222 · Cited by 339
“Bacterial -glucuronidase activity can be pharmacologically blocked (26), but an effect on estrogens has not yet been demonstrated.”
BackgroundBioaccumulation of therapeutic drugs by human gut bacteria
Klünemann, M., Andrejev, S., Blasche, S., Mateus, A., Phapale, P., Devendran, S., Vappiani, J., Simon, B., Scott, T. A., Kafkia, E., et al. (2021) · Nature · doi:10.1038/s41586-021-03891-8 · Cited by 327
Gut microbiome, big data and machine learning to promote precision medicine for cancer
Cammarota, G., Ianiro, G., Ahern, A., Carbone, C., Temko, A., Claesson, M. J., Gasbarrini, A., & Tortora, G. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0327-3 · Cited by 324
Gut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319
“…the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity…”
BackgroundInfluentialMicrobiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
Challenges and opportunities of metabolomics
Johnson, C. H., & Gonzalez, F. J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24002 · Cited by 311
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Panebianco, C., Andriulli, A., & Pazienza, V. (2018) · Microbiome · doi:10.1186/s40168-018-0483-7 · Cited by 298
Blaser, M. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78366 · Cited by 297
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine
Heinken, A., Hertel, J., Acharya, G., Ravcheev, D. A., Nyga, M., Okpala, O. E., Hogan, M., Magnúsdóttir, S., Martinelli, F., Nap, B., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01628-0 · Cited by 290
Manipulating Bacterial Communities by in situ Microbiome Engineering
Sheth, R. U., Cabral, V., Chen, S. P., & Wang, H. H. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.01.005 · Cited by 290
Self-citationAn atlas of β-glucuronidases in the human intestinal microbiome
Pollet, R. M., D'Agostino, E. H., Walton, W. G., Xu, Y., Little, M. S., Biernat, K. A., Pellock, S. J., Patterson, L. M., Creekmore, B. C., Isenberg, H. N., et al. (2017) · Structure · doi:10.1016/j.str.2017.05.003 · Cited by 289
Self-citationWallace, B. D., Roberts, A. B., Pollet, R. M., Ingle, J. D., Biernat, K. A., Pellock, S. J., Venkatesh, M. K., Guthrie, L., O’Neal, S. K., Robinson, S. J., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.08.005 · Cited by 285
“This result is reminiscent of the data collected previously on the mammalian GUS from bovine, which was also not subject to inhibition by Inhibitors 1–8 (Roberts et al., 2013; Wallace et al., 2010).”
InfluentialSelf-citationGut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.018 · Cited by 283
Dysbiosis of gut microbiota in promoting the development of colorectal cancer
Zou, S., Fang, L., & Lee, M.-H. (2018) · Gastroenterology Report · doi:10.1093/gastro/gox031 · Cited by 280
The influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
A selective gut bacterial bile salt hydrolase alters host metabolism
Yao, L., Seaton, S. C., Ndousse-Fetter, S., Adhikari, A. A., DiBenedetto, N., Mina, A. I., Banks, A. S., Bry, L., & Devlin, A. S. (2018) · eLife · doi:10.7554/elife.37182 · Cited by 274
Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism
Hu, S., Ding, Q., Zhang, W., Kang, M., Ma, J., & Zhao, L. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2236749 · Cited by 274
Microbiome at the Frontier of Personalized Medicine
Kashyap, P. C., Chia, N., Nelson, H., Segal, E., & Elinav, E. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.10.004 · Cited by 274
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Carmody, R. N., & Turnbaugh, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72335 · Cited by 268
“Coadministration of irinotecan together with one of these inhibitors substantially reduced diarrheal symptoms in mice and protected gastrointestinal epithelial cells against inflammation (53).”
InfluentialDrug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Microbiome, Inflammation, and Cancer
Francescone, R., Hou, V., & Grivennikov, S. I. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000048 · Cited by 266
Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer
Bultman, S. J. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500902 · Cited by 265
Ma, Z., Zuo, T., Frey, N., & Rangrez, A. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01946-6 · Cited by 259
Gut microbiota, inflammation and colorectal cancer
Sun, J., & Kato, I. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.03.004 · Cited by 257
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments
McQuade, R. M., Stojanovska, V., Abalo, R., Bornstein, J. C., & Nurgali, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00414 · Cited by 252
Taking it Personally: Personalized Utilization of the Human Microbiome in Health and Disease
Zmora, N., Zeevi, D., Korem, T., Segal, E., & Elinav, E. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2015.12.016 · Cited by 252
Proteobacteria explain significant functional variability in the human gut microbiome
Bradley, P. H., & Pollard, K. S. (2017) · Microbiome · doi:10.1186/s40168-017-0244-z · Cited by 249
“Shotgun metagenomics is revolutionizing our ability to identify protein-coding genes from these microbes and associate gene levels with disease [6], drug efficacy [7] or sideeffects [8], and other host traits.”
BackgroundAntimicrobial Resistance and Its Spread Is a Global Threat
Aljeldah, M. M. (2022) · Antibiotics · doi:10.3390/antibiotics11081082 · Cited by 247
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Emerging roles of the microbiome in cancer
Bultman, S. J. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt392 · Cited by 239
Therapeutic Modulation of Microbiota-Host Metabolic Interactions
Holmes, E., Kinross, J., Gibson, G. R., Burcelin, R., Jia, W., Pettersson, S., & Nicholson, J. K. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004244 · Cited by 236
Dou, W., Zhang, J., Sun, A., Zhang, E., Ding, L., Mukherjee, S., Wei, X., Chou, G., Wang, Z.-T., & Mani, S. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512005594 · Cited by 235
Self-citationGlucuronides in the gut: Sugar-driven symbioses between microbe and host
Pellock, S. J., & Redinbo, M. R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.767434 · Cited by 225
Self-citationTargeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy
Bhatt, A. P., Pellock, S. J., Biernat, K. A., Walton, W. G., Wallace, B. D., Creekmore, B. C., Letertre, M. M., Swann, J. R., Wilson, I. D., Roques, J. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918095117 · Cited by 221
Self-citationThe promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Glucuronidation: driving factors and their impact on glucuronide disposition
Yang, G., Ge, S., Singh, R., Basu, S., Shatzer, K., Zen, M., Liu, J., Tu, Y., Zhang, C., Wei, J., et al. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293682 · Cited by 215
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · Cancer Communications · doi:10.1002/cac2.12178 · Cited by 214
Human Gut Microbiota and Drug Metabolism
Pant, A., Maiti, T. K., Mahajan, D., & Das, B. (2023) · Microbial Ecology · doi:10.1007/s00248-022-02081-x · Cited by 212
Epidemiologic studies of the human microbiome and cancer
Vogtmann, E., & Goedert, J. J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.465 · Cited by 211
Pharmacomicrobiomics: a novel route towards personalized medicine?
Doestzada, M., Vila, A. V., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., Kuipers, F., Wijmenga, C., & Fu, J. (2018) · Protein & Cell · doi:10.1007/s13238-018-0547-2 · Cited by 210
One Health Relationships Between Human, Animal, and Environmental Microbiomes: A Mini-Review
Trinh, P., Zaneveld, J. R., Safranek, S., & Rabinowitz, P. M. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00235 · Cited by 209
Microbiota effects on cancer: From risks to therapies
Rea, D., Coppola, G., Palma, G., Barbieri, A., Luciano, A., Del Prete, P., Rossetti, S., Berretta, M., Facchini, G., Perdonà, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24681 · Cited by 208
“After intravenous administration CTP-11 is transformed in SN38 produced by carboxylesterases and is glucuronidated in the liver by uridine diphosphate (UDP)–glucuronosyltransferase enzymes to form inactive SN-38G which is excreted via the biliary ducts into the gastrointestinal (GI) tract; When it reaches the bowel, i…”
BackgroundThe microbiome in prostate inflammation and prostate cancer
Porter, C. M., Shrestha, E., Peiffer, L. B., & Sfanos, K. S. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0041-1 · Cited by 207
Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids
Klaassen, C. D., & Cui, J. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065698 · Cited by 201
Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy
Wang, G., Yu, Y., Wang, Y., Wang, J., Guan, R., Sun, Y., Shi, F., Gao, J., & Fu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28436 · Cited by 199
Zhang, Y., Chen, R., Zhang, D., Qi, S., & Liu, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114295 · Cited by 198
Haiser, H. J., Seim, K. L., Balskus, E. P., & Turnbaugh, P. J. (2014) · Gut Microbes · doi:10.4161/gmic.27915 · Cited by 197
“A seminal example of the value of such studies comes from work by Redinbo and colleagues.(9-11) Their research has shown that inhibition of microbial β-glucuronidase activity ameliorates the enteric side effects of the chemotherapeutic drug, irinotecan, and multiple non-steroidal anti-inflammatory drugs.”
MethodLoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R., & Boelsterli, U. A. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191122 · Cited by 197
Self-citationGut Microbiota Shapes the Efficiency of Cancer Therapy
Ma, W., Mao, Q., Xia, W., Dong, G., Yu, C., & Jiang, F. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01050 · Cited by 192
Goodman, B., & Gardner, H. (2018) · The Journal of Pathology · doi:10.1002/path.5047 · Cited by 187
Developing a metagenomic view of xenobiotic metabolism
Haiser, H. J., & Turnbaugh, P. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.07.009 · Cited by 186
“Finally, the authors demonstrated that co-administration of irinotecan with the inhibitor in a mouse model dramatically reduced the incidence of diarrhea, and protected intestinal tissues by showing a marked reduction in gut epithelial cell inflammation [10].”
BackgroundInfluential
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.